Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Published Date: 11 Sep 2024

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

2.

AI Unlocks Benefits of Prostate Cancer Treatment.

3.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

4.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.

5.

Is Exercise an Effective Treatment for Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot